What HCPs say could reveal prescribing intent

Tern plc

Talking Medicines is targeting a specific problem for pharmaceutical companies, understanding what actually influences healthcare professionals before they decide whether to prescribe a medicine.

Pharmaceutical marketing teams typically track reach, impressions, clicks and engagement to measure the impact of campaigns. These figures show whether HCPs have seen or interacted with content, but they do not necessarily explain why a doctor may consider, reject or continue using a particular treatment.

Talking Medicines says prescribing intent is influenced by several factors, including clinical evidence, treatment experience, tolerability, contraindications, administration, monitoring requirements, treatment alternatives and local guidelines. Patient requests and discussions with pharmaceutical representatives can also influence how medicines are considered.

This creates a gap between marketing activity and prescribing intent. A campaign can generate strong engagement without addressing the questions or concerns that are affecting treatment decisions.

The company is using analysis of HCP conversations to address that gap. Its DrugVoice platform analyses unstructured conversations using artificial intelligence, natural language processing and healthcare-specific data science.

Rather than simply measuring how frequently a medicine is mentioned, the platform looks at what HCPs are saying about it. This can include discussions around clinical evidence, treatment experience, tolerability, differentiation, patient suitability and unmet needs.

For pharmaceutical companies, this information can provide a clearer view of the issues influencing treatment consideration. It can also show whether the messages being delivered through marketing campaigns reflect the issues HCPs are discussing in practice.

The distinction between exposure and intent is significant. Two medicines could receive similar levels of marketing engagement while generating very different conversations among HCPs. One may be discussed positively in relation to a particular patient group, while another may attract questions about tolerability or differentiation.

Talking Medicines is therefore focused on turning conversations that would otherwise remain unstructured into information that pharmaceutical companies can analyse.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search